Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Kidney Neoplasms × pazopanib × Clear all

Phase

Status

Sponsor Class

OTHER 5 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 26 Neoplasms 11 Sarcoma 8 Breast Neoplasms 7 Ovarian Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Neoplasm Metastasis 5 Fallopian Tube Neoplasms 3 Colorectal Neoplasms 3 Hemangiosarcoma 2 Clear-cell metastatic renal cell carcinoma 2 Carcinoma, Ovarian Epithelial 2 Uterine Diseases 1 Uterine Cervical Neoplasms 1 Uterine Cervical Diseases 1 Solid Tumours 1 Sarcoma, Synovial 1 Recurrence 1 Prostatic Neoplasms 1 Patient Preference 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neoplasms, Plasma Cell 1 Melanoma 1 Liver Neoplasms 1 Leiomyosarcoma 1 Kidney Neoplasms 1 Inflammatory Breast Neoplasms 1 Coronary Artery Disease 1

Interventions

pembrolizumab 14 Nivolumab 13 Sunitinib 10 cabozantinib 8 belzutifan 8 Ipilimumab 6 Axitinib 6 Everolimus 5 temsirolimus 3 perifosine 3 atezolizumab 3 Sorafenib 3 motexafin gadolinium 2 liposomal doxorubicin 2 lenvatinib 2 entinostat 2 ciforadenant 2 belinostat 2 avelumab 2 Paclitaxel 2 G250 monoclonal antibody 2 Fluorouracil 2 Drug Therapy 2 Docetaxel 2 Dexamethasone 2 Carboplatin 2 Biopsy 2 zimberelimab 1 vitespin 1 vinflunine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03200717 2023-08-21

IO-PAZ

Novartis

Phase 2 Completed

62 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡